Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018

Abbad, Anass; Perera, Ranawaka A.P.M.; Anga, Latifa; Faouzi, Abdellah; Minh, Nhu Nguyen Tran; Malik, Sk Md Mamunur Rahman; Iounes, Nadia; Maaroufi, Abderrahmane; Kerkhove, Maria D. Van; Peiris, Malik; Nourlil, Jalal

doi:10.2807/1560-7917.es.2019.24.48.1900244

Cited by 19 publications

(19 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, given that Wuhan is no longer the only (albeit the first) location with sustained local spread, it would be important to assess and take into account the experience from elsewhere, both domestically in mainland China and overseas. These secondary epicenters, having learned from the early phase of the Wuhan epidemic, might have had a systematically different epidemiology and response that could impact the parameters estimated here [21][22][23][24][25][26][27][28][29][30][31] .…”

Section: Nature Medicinementioning

confidence: 99%

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Leung

Bushman

et al. 2020

Nat Med

1,182

945

View full text Add to dashboard Cite

As of 29 February 2020 there were 79,394 confirmed cases and 2,838 deaths from COVID-19 in mainland China. Of these, 48,557 cases and 2,169 deaths occurred in the epicenter, Wuhan. A key public health priority during the emergence of a novel pathogen is estimating clinical severity, which requires properly adjusting for the case ascertainment rate and the delay between symptoms onset and death. Using public and published information, we estimate that the overall symptomatic case fatality risk (the probability of dying after developing symptoms) of COVID-19 in Wuhan was 1.4% (0.9-2.1%), which is substantially lower than both the corresponding crude or naïve confirmed case fatality risk (2,169/48,557 = 4.5%) and the approximator 1 of deaths/ deaths + recoveries (2,169/2,169 + 17,572 = 11%) as of 29 February 2020. Compared to those aged 30-59 years, those aged below 30 and above 59 years were 0.6 (0.3-1.1) and 5.1 (4.2-6.1) times more likely to die after developing symptoms. The risk of symptomatic infection increased with age (for example, at ~4% per year among adults aged 30-60 years).On 9 January 2020, the novel coronavirus SARS-CoV-2 was officially identified as the cause of the COVID-19 outbreak in Wuhan, China. One of the most critical clinical and public health questions during the emergence of a completely novel pathogen, especially one that could cause a global pandemic, pertains to the spectrum of illness presentation or severity profile. For the patient and clinician, this affects triage and diagnostic decision-making, especially in settings without ready access to laboratory testing or when surge capacity has been exceeded. It also influences therapeutic choice and prognostic expectations. For managers of health services, it is important for rapid forward planning in terms of procurement of supplies, readiness of human resources to staff beds at different intensities of care and generally ensuring the sustainability of the health system through the peak and duration of the epidemic.At the population level, determining the shape and size of the 'clinical iceberg' 2,3 , both above and below the observed threshold (in turn determined by symptomatology, care-seeking behavior and clinical access), is key to understanding the transmission dynamics and interpreting epidemic trajectories. Specifically, delineating the proportion of infections that are clinically unobserved under different circumstances is critical to refining model parameterization. In turn, estimates of both the observed and unobserved infections are essential for informing the development and evaluation of public health strategies, which need to be traded off against economic, social and personal freedom costs. For example, drastic social distancing and mobility restrictions, such as school closures and travel advisories/bans, should only be considered if an accurate estimation

show abstract

Section: Nature Medicinementioning

confidence: 99%

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Leung

Bushman

et al. 2020

Nat Med

1,182

945

View full text Add to dashboard Cite

show abstract

“…* IFR=CFR=HFR given virtually every infected person required hospitalization and seroprevalence amongst close contacts and in general community approximated zero ** Among probable cases *** Among laboratory-confirmed cases † There are more infections "undetected" in MERS compared with SARS. The seroprevalence amongst individuals exposed to camels was estimated as 6.2% in Arabian Peninsula 22 .…”

Section: Discussionmentioning

confidence: 99%

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Leung

Bushman

et al. 2020

Preprint

408

434

View full text Add to dashboard Cite

As of February 13, 2020, there have been 59,863 laboratory-confirmed cases of COVID-19 infections in mainland China, including 1,367 deaths. A key public health priority during the emergence of a novel pathogen is estimating clinical severity. Here we estimated the symptomatic case-fatality risk (sCFR; the probability of dying from the infection after developing symptoms) of COVID-19 in Wuhan using public and published information. We estimated that sCFR was 0.5% (0.1%-1.3%), 0.5% (0.2%-1.1%) and 2.7% (1.5%-4.7%) for those aged 15-44, 45-64 and >64 years. The overall sCFR among those aged ≥15 years was 1.4% (0.8%-2.0%). Authors Joseph T Wu and Kathy Leung contributed equally to this work

show abstract

“…In joined together United States of America, more than 5,87,155 cases tainted by COVID-19 have been affirmed, and number is still rising. As the COVID-19 flare-up quickly advances, inquire about work to create an immunization and to test antivirals and other therapeutics proceeds in parallel to other measures (Abbad et al, 2019;Ahmed et al, 2020;Boldog et al, 2020;De Salazar et al, 2020). At present, there are no effective drugs available for control of coronaviruses infection causes COVID-19.…”

Section: Introductionmentioning

confidence: 99%

Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures

Kumar

Kumari

Jayaraj

et al. 2020

Journal of Biomolecular Structure and Dynamics

View full text Add to dashboard Cite

The current outbreak of a novel coronavirus, named as SARS-CoV-2 causing COVID-19 occurred in 2019, is in dire need of finding potential therapeutic agents. Recently, ongoing viral epidemic due to coronavirus (SARS-CoV-2) primarily affected mainland China that now threatened to spread to populations in most countries of the world. In spite of this, there is currently no antiviral drug/ vaccine available against coronavirus infection, COVID-19. In the present study, computer-aided drug design-based screening to find out promising inhibitors against the coronavirus (SARS-CoV-2) leads to infection, COVID-19. The lead therapeutic molecule was investigated through docking and molecular dynamics simulations. In this, binding affinity of noscapines(23B)-protease of SARS-CoV-2 complex was evaluated through MD simulations at different temperatures. Our research group has established that noscapine is a chemotherapeutic agent for the treatment of drug resistant cancers; however, noscapine was also being used as anti-malarial, anti-stroke and cough-suppressant. This study suggests for the first time that noscapine exerts its antiviral effects by inhibiting viral protein synthesis. ARTICLE HISTORY

show abstract

Middle East respiratory syndrome coronavirus (MERS-CoV) neutralising antibodies in a high-risk human population, Morocco, November 2017 to January 2018

Cited by 19 publications

References 26 publications

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Estimating clinical severity of COVID-19 from the transmission dynamics in Wuhan, China

Understanding the binding affinity of noscapines with protease of SARS-CoV-2 for COVID-19 using MD simulations at different temperatures

Contact Info

Product

Resources

About